)
Visual
test
Ajanta Pharma
Ajanta Pharma (AJANTPHARM) investor relations material
Ajanta Pharma Q3 25/26 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 25/26 earnings summary30 Jan, 2026
Executive summary
Revenue from operations grew 20% year-over-year in Q3 FY26 to ₹1,375 crore, with PAT up 18% to ₹274 crore.
For the nine months ended December 2025, revenue rose 16% to ₹4,031 crore and PAT increased 14% to ₹789 crore.
Branded generics remain the core business, contributing 71% of 9M FY26 sales, with India, Asia, and Africa as key markets.
US generics segment showed robust performance, with a 13% CAGR over five years and 26% of 9M FY26 revenue.
All business segments are broadly in line with plans, with strong performance in India and U.S. generics, and confidence in sustaining growth momentum.
Financial highlights
Q3 FY26 revenue: ₹1,375 crore (up 20% YoY); 9M FY26 revenue: ₹4,031 crore (up 16% YoY); Q3 PAT: ₹274 crore (up 18% YoY); 9M PAT: ₹789 crore (up 14% YoY).
EBITDA for Q3: ₹382 crore (up 19%); 9M: ₹1,061 crore (up 10%); adjusted 9M EBITDA (ex-forex loss): ₹1,123 crore (up 15%).
EBITDA margin: 28% for Q3, 26% for 9M; adjusted 28% for 9M FY26.
Gross margin: 79% for Q3, 78% for 9M; expected to remain around 78% ±1% for FY26.
Earnings per share for 9M FY26: ₹63.18 basic, ₹63.17 diluted.
Outlook and guidance
Confident of maintaining full-year growth and EBITDA margin guidance of 27% ±1%.
Focus on new product launches, expanding into new countries and therapies, and enhancing field force productivity.
Asia branded business expected to post mid- to high-single-digit growth for FY26; Africa branded business to post low double-digit growth.
U.S. generics expected to deliver double-digit growth in FY27, though not at the same pace as FY26.
Continued emphasis on cost optimization and digitalization across functions.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 021240
3Q'25 saw record revenue and operating profit, with robust growth in both domestic and overseas markets. - KPIL
27% YOY revenue growth, margin gains, and lower net debt drive a strong multi-year outlook. - BN4
Net profit rose 39% to SGD 1.1B, FUM hit SGD 95B, and shareholder returns surged 58.5%. - HEXT
Full-year revenue rose 7.6% with margin expansion and strong deal wins; 2026 growth to accelerate. - S68
Record revenue, strong segment growth, and a robust IPO pipeline drive positive outlook. - 4183
Lower sales and profits prompt revised guidance and major capital actions, including a stock split. - 6723
Strong AI and industrial demand drive results; timing business sold for $3B; inventory targets raised. - 4902
Operating profit rebounded sharply on cost controls and gains, despite lower revenue. - 032640
Net profit surged 61.9% YoY on strong wireless, broadband, and AIDC growth. - 6417
Strong pachinko sales drove revenue growth, with major treasury stock cancellation planned.
Next Ajanta Pharma earnings date
Q4 25/2630 Apr, 2026
Ajanta Pharma
Next Ajanta Pharma earnings date
Q4 25/2630 Apr, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Ajanta Pharma Limited is a pharmaceutical company engaged in the development, manufacturing, and marketing of generic and branded pharmaceutical formulations. The company focuses on therapeutic segments such as ophthalmology, dermatology, cardiology, and pain management. Ajanta Pharma serves domestic and international markets, supplying products across regulated and emerging markets. The company is headquartered in Mumbai, India, and its shares are listed on the BSE.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage